ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 36735893

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.

Novello S and 17 others. J Clin Oncol, 2023. Cited by 509 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Papers, record 36735893. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36735893

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
PubMed
Journal
J Clin Oncol
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
509
iCite
Relative citation ratio, by iCite
41.8
iCite
Revised in PubMed
2023-09-11
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Novello SSilviahttps://orcid.org/0000-0001-7653-9748
2Kowalski DMDariusz Mhttps://orcid.org/0000-0002-9452-3229
3Luft AAlexander
4Gümüş MMahmuthttps://orcid.org/0000-0003-3550-9993
5Vicente DDavid
6Mazières JJulienhttps://orcid.org/0000-0002-5921-7613
7Rodríguez-Cid JJeronimohttps://orcid.org/0000-0001-8518-9065
8Tafreshi AAli
9Cheng YYinghttps://orcid.org/0000-0001-9908-597X
10Lee KHKi Hyeonghttps://orcid.org/0000-0002-7830-5950

1 to 10 of 18Source PubMed

See all 18 authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Carcinoma, Squamous CellMajor topic
Humans
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02775435A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)Derived from the trialYes

Source ClinicalTrials.gov

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in37,691,862KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer.https://conductscience.org/library/papers/37691862PubMed
Comment in37,691,870Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study.https://conductscience.org/library/papers/37691870PubMed

References5

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130,280,635Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.N Engl J Med2018https://conductscience.org/library/papers/30280635PubMed
236,809,080Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.J Clin Oncol2023https://conductscience.org/library/papers/36809080PubMed
311,784,875Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med2002https://conductscience.org/library/papers/11784875PubMed
432,599,071A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.J Thorac Oncol2020https://conductscience.org/library/papers/32599071PubMed
533,872,070Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.J Clin Oncol2021https://conductscience.org/library/papers/33872070PubMed

Cited by380

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 509 citations.

PMIDTitleJournalYearIn PapersSource
42,964,339Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial.EClinicalMedicine2026https://conductscience.org/library/papers/42964339PubMed
42,955,647Prognostic impact of lung dose during radiotherapy on patients with lung cancer in the era of immunotherapy.Clin Transl Oncol2026https://conductscience.org/library/papers/42955647PubMed
42,955,396ATR inhibition potentiates immunotherapy efficacy via TBK1-NFκB signaling and autophagy blockade in non-small cell lung cancer.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42955396PubMed
42,947,700Economic evaluation of six immune checkpoint inhibitor-based first-line therapies for advanced squamous non-small-cell lung cancer: a cost-effectiveness analysis based on network meta-analysis.Front Pharmacol2026https://conductscience.org/library/papers/42947700PubMed
42,939,986Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer.Biomedicines2026https://conductscience.org/library/papers/42939986PubMed
42,930,173Cancer Immunotherapy and Immune-Related Adverse Events: Focusing on Non-Small Cell Lung Cancer.Curr Oncol2026https://conductscience.org/library/papers/42930173PubMed
42,909,913Targeting NCAPG with Arundanine Suppresses Neutrophil/NET-Mediated Immune Evasion and Enhances CD8+ T Cell Function in Lung Squamous Cell Carcinoma.Int J Biol Sci2026https://conductscience.org/library/papers/42909913PubMed
42,875,050Plasma cell-free RNA ITGB3 is associated with long-term clinical benefit in patients with non-small cell lung cancer receiving immunochemotherapy.J Immunother Cancer2026https://conductscience.org/library/papers/42875050PubMed
42,856,948Adoptive cell therapy in lung cancer: progress, challenges, and prospects.Chin Med J Pulm Crit Care Med2026https://conductscience.org/library/papers/42856948PubMed
42,856,614Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chin Med J Pulm Crit Care Med2026https://conductscience.org/library/papers/42856614PubMed

1 to 10 of 380

See all 380 cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
PDCD15,133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CARBOPLATINCHEMBL1351Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1351ChEMBL
PEMBROLIZUMABCHEMBL3137343Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3137343ChEMBL
PACLITAXELCHEMBL428647Derived from the trial1https://conductscience.org/library/drugs/CHEMBL428647ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36735893

GET https://conductscience.org/api/papers/v1/36735893/cited_by?page=2

API referenceFor AI assistants